uniQure N.V. (NASDAQ:QURE) – Stock analysts at Leerink Swann issued their FY2019 earnings per share estimates for uniQure N.V. in a research report issued on Wednesday. Leerink Swann analyst J. Schwartz anticipates that the biotechnology company will post earnings per share of ($1.95) for the year. Leerink Swann also issued estimates for uniQure N.V.’s FY2020 earnings at ($2.05) EPS.
uniQure N.V. (NASDAQ:QURE) last released its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.78) by $0.05. uniQure N.V. had a negative return on equity of 135.97% and a negative net margin of 203.99%. The company had revenue of $4.94 million for the quarter, compared to analyst estimates of $2.92 million. COPYRIGHT VIOLATION NOTICE: “Leerink Swann Weighs in on uniQure N.V.’s FY2019 Earnings (QURE)” was first published by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this story on another site, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this story can be read at https://stocknewstimes.com/2017/08/12/leerink-swann-weighs-in-on-uniqure-n-v-s-fy2019-earnings-qure.html.
QURE has been the topic of a number of other reports. Chardan Capital set a $13.00 target price on shares of uniQure N.V. and gave the stock a “buy” rating in a research report on Sunday, July 23rd. Zacks Investment Research raised shares of uniQure N.V. from a “sell” rating to a “hold” rating and set a $9.25 target price on the stock in a research report on Wednesday. Cowen and Company reissued a “buy” rating on shares of uniQure N.V. in a research report on Wednesday, May 24th. Oppenheimer Holdings, Inc. reissued an “outperform” rating and set a $17.00 target price on shares of uniQure N.V. in a research report on Friday, June 30th. Finally, ValuEngine raised shares of uniQure N.V. from a “sell” rating to a “hold” rating in a research report on Monday, July 24th. One analyst has rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $15.04.
uniQure N.V. (NASDAQ QURE) traded up 1.80% on Thursday, hitting $8.50. 91,071 shares of the company traded hands. The stock’s 50-day moving average is $7.31 and its 200 day moving average is $6.08. uniQure N.V. has a 12 month low of $4.72 and a 12 month high of $9.72. The stock’s market cap is $216.27 million.
A number of hedge funds have recently bought and sold shares of the stock. FMR LLC boosted its stake in uniQure N.V. by 27.5% in the first quarter. FMR LLC now owns 1,498,463 shares of the biotechnology company’s stock valued at $8,661,000 after buying an additional 323,345 shares in the last quarter. P.A.W. Capital Corp bought a new stake in uniQure N.V. during the first quarter valued at about $867,000. Oxford Asset Management bought a new stake in uniQure N.V. during the first quarter valued at about $100,000. Paloma Partners Management Co boosted its stake in uniQure N.V. by 717.7% in the first quarter. Paloma Partners Management Co now owns 85,000 shares of the biotechnology company’s stock valued at $491,000 after buying an additional 74,605 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its stake in uniQure N.V. by 6.8% in the fourth quarter. Renaissance Technologies LLC now owns 251,300 shares of the biotechnology company’s stock valued at $1,407,000 after buying an additional 15,950 shares in the last quarter. 30.22% of the stock is currently owned by hedge funds and other institutional investors.
In related news, insider Harald Petry sold 58,075 shares of the company’s stock in a transaction on Monday, June 26th. The shares were sold at an average price of $6.01, for a total value of $349,030.75. Following the sale, the insider now directly owns 155 shares of the company’s stock, valued at $931.55. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 173,460 shares of company stock worth $1,042,986 over the last ninety days. 0.64% of the stock is currently owned by corporate insiders.
About uniQure N.V.
Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.
Receive News & Ratings for uniQure N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure N.V. and related companies with MarketBeat.com's FREE daily email newsletter.